BioSpace News Archive

Pulse Biosciences, Inc., a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, announced plans to participate in the Stephens Annual Investment Conference in Nashville, Tennessee.

OptiNose, Inc., a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that the company has granted a non-qualified stock option awards to purchase an aggregate of 53,500 shares of its common stock to six new employees as an inducement material for accepting employment with OptiNose.

Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

Athenex, Inc. today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development will present at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 3:55 pm ET.

VYNE Therapeutics Inc. today announced that David Domzalski, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

Cognition Therapeutics, Inc. today reported consolidated financial results for the third quarter ended September 30, 2021.

Day One Biopharmaceuticals today announced that management will participate in a fireside chat discussion at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Fountain Therapeutics today announced a $15 million Series A-2 financing, which brings its total Series A funding to $26 million.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today released positive interim data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the first-in-man Phase 1 ReSPECT™-GBM clinical trial in patients with recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology Annual Meeting and Education Day being held in Boston, Massachusetts.

AL-S Pharma AG, announced today enrollment of the first patient in a multicenter, placebo-controlled Phase 2 clinical trial to evaluate AP-101 in patients with amyotrophic lateral sclerosis (ALS). AP-101 is a human antibody directed against misfolded superoxide dismutase 1 (SOD1).